NCT04756921View on ClinicalTrials.gov

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

July 24, 2020

Study Completion Date

July 24, 2020

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

Pyrotinib

Pyrotinib 400mg po qd

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Biyun Wang, MD

OTHER

NCT04756921 - 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response | Biotech Hunter | Biotech Hunter